Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Lab ; 57(9-10): 669-75, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22029181

RESUMO

BACKGROUND: The present proficiency study aimed to elucidate the comparability and reliability of test systems for the determination of AFP concentrations. METHODS: 25 laboratories using 8 different commercial test systems used liquid BIOREF-AFP control serum in their routine internal quality control over a period of one year. For statistical analysis the results were collected centrally. RESULTS: The statistical analysis of the test results revealed considerable variation for the different laboratories. The deviations of the mean values of different laboratories from the overall mean value varied between 0.1 and 26.1%, and for most of the laboratories the deviation was round about 10%. The precision of measured values in the individual laboratories was in most cases acceptable: Nevertheless, the coefficients of variation of the individual laboratories ranged from 13 to 16.1%. CONCLUSIONS: In conclusion, this study indicates that AFP results vary between different laboratories albeit an international standard for AFP is available. Therefore, every laboratory should participate in external ring studies and should use a quality control serum independent of the test kit manufacturer for the internal quality control.


Assuntos
Técnicas de Laboratório Clínico/normas , Kit de Reagentes para Diagnóstico/normas , alfa-Fetoproteínas/análise , Adulto , Linhagem Celular Tumoral , Técnicas de Laboratório Clínico/estatística & dados numéricos , Feminino , Humanos , Cooperação Internacional , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/diagnóstico , Masculino , Neoplasias Embrionárias de Células Germinativas/sangue , Neoplasias Embrionárias de Células Germinativas/diagnóstico , Gravidez , Valores de Referência , Reprodutibilidade dos Testes
2.
Clin Lab ; 55(5-6): 201-6, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19728553

RESUMO

BACKGROUND: Because of the vast range of physiological relevant estradiol concentrations the requirements to be met by an estradiol assay are high. In the present study the performance of various commercially available estradiol assays was evaluated with regard to imprecision and long-term stability. METHODS: Precision and long-term stability of 7 commercially available estradiol immunoassays were assessed in a multi-centre quality control study based on the repeated measurement of liquid BIOREF estradiol control sera by 18 laboratories during a 14-month study period. RESULTS: The mean estradiol concentrations determined in 594 runs performed for each control level were 71 pg/ml, 349 pg/ml and 676 pg/ml. A high variation was found for the method specific mean values calculated from all results measured with the same method, which ranged between 32 - 90 pg/ml, 187 - 392 pg/ml and 373 - 790 pg/ml, resulting in a similar high inter-laboratory variation with coefficients of variation (CVs) of 25.0%, 16.7% and 17.5%. In contrast, the intra-laboratory variation of estradiol values as well as the variation of values measured with the same method were found to be considerably lower with coefficients of variation < 10% for most laboratories and methods; only the low control level was measured with CV values > 10% by the majority of laboratories and methods. For none of the laboratories a tendency was observed in the results from beginning to end of the 14 month study period indicating a high uniformity in assay production and a good long-term stability of the control material used. CONCLUSIONS: The present data demonstrate that also with the currently available estradiol immunoassays the comparability of results measured with different methods is limited. With most assays very low estradiol concentrations, as observed in postmenopausal women, can be determined only with a precision which is not adequate for clinical assessment.


Assuntos
Estradiol/sangue , Imunoensaio/normas , Estabilidade de Medicamentos , Feminino , Fase Folicular/fisiologia , Humanos , Laboratórios/normas , Masculino , Pós-Menopausa , Controle de Qualidade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Caracteres Sexuais
3.
Langenbecks Arch Surg ; 394(2): 221-6, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19034493

RESUMO

BACKGROUND: Adequate indication and duration of administration are central issues of modern antibiotic treatment in intensive care medicine. The biochemical variable procalcitonin (PCT) is known to indicate systemically relevant bacterial infections with high accuracy. In the present study, we aimed to investigate the clinical usefulness of PCT for guiding antibiotic treatment in surgical intensive care patients with severe sepsis. PATIENTS AND METHODS: Patients were randomly assigned to a PCT-guided or a control group requiring antibiotic treatment. All patients received a calculated antibiotic regimen according to the presumed microbiological spectrum. In the PCT-guided group, antibiotic treatment was discontinued if clinical signs of infection improved and the PCT value was either <1 ng/ml or decreased to <35% of the initial concentration within three consecutive days. In the control group, antibiotic treatment was directed by empirical rules. RESULTS: The PCT-guided group (n = 14 patients) and the control group (n = 13 patients) did not differ in terms of biological variables, underlying diseases, and overall disease severity. PCT guidance led to a significant reduction of antibiotic treatment from 6.6 +/- 1.1 days (mean +/- SD) compared with 8.3 +/- 0.7 days in control patients (p < 0.001) along with a reduction of antibiotic treatment costs of 17.8% (p < 0.01) without any adverse effects on outcome. CONCLUSIONS: Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients with severe sepsis. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistances and costs in intensive care medicine.


Assuntos
Algoritmos , Antibacterianos/administração & dosagem , Calcitonina/sangue , Cuidados Críticos , Precursores de Proteínas/sangue , Sepse/sangue , Sepse/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Proteína C-Reativa/metabolismo , Peptídeo Relacionado com Gene de Calcitonina , Esquema de Medicação , Feminino , Mortalidade Hospitalar , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/tratamento farmacológico , Valor Preditivo dos Testes , Estudos Prospectivos , Sepse/mortalidade
4.
Anaesthesist ; 57(6): 571-7, 2008 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-18463831

RESUMO

The development of resistance by infective bacterial species is an incentive to reconsider the indications and administration of available antibiotics. Correct recognition of the indications and duration of therapy are particularly important for the use of highly potent substances in the intensive care situation. There has as yet been no clinical chemical parameter which is capable of specifically distinguishing a bacterial infection from a viral or non-infectious inflammatory reaction, but it now appears that procalcitonin (PCT) offers this possibility. The present study was intended to clarify whether PCT can be used to guide antibiotic therapy in surgical intensive care patients. A total of 110 patients in a surgical intensive care ward receiving antibiotic therapy after confirmed infection or a high grade suspicion of infection were enrolled in this study. In 57 of these patients a new decision was reached each day as to whether the antibiotic therapy should be continued after daily PCT determination and clinical assessment. The control group consisted of 53 patients with a standardized duration of antibiotic therapy over 8 days. Demographic and clinical data were comparable in both groups. However, in the PCT group the duration of antibiotic therapy was significantly shorter compared to controls (5.9+/-1.7 vs. 7.9+/-0.5 days, p<0.001) without unfavorable effects on clinical outcome.


Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Calcitonina/sangue , Cuidados Críticos/métodos , Precursores de Proteínas/sangue , Síndrome de Resposta Inflamatória Sistêmica/tratamento farmacológico , Idoso , Infecções Bacterianas/complicações , Infecções Bacterianas/psicologia , Biomarcadores , Peptídeo Relacionado com Gene de Calcitonina , Cuidados Críticos/psicologia , Farmacorresistência Bacteriana , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sepse/tratamento farmacológico , Síndrome de Resposta Inflamatória Sistêmica/etiologia , Síndrome de Resposta Inflamatória Sistêmica/psicologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA